The abstract is read at the publisher; the summary is JClub's.
Intrathecal QH104, an allogeneic B7-H3-targeted CAR γδ T-cell therapy, showed no grade ≥4 treatment-related adverse events in 3 leptomeningeal metastasis patients.
- Why it matters: Leptomeningeal metastasis from solid tumors has limited effective options, and intrathecal cellular therapies need early safety and activity signals plus local immune evidence.
- What they did: In a phase I trial (NCT06592092), 3 patients with B7-H3-positive solid tumors received 3×107 QH104 cells per infusion via lumbar puncture or an Ommaya reservoir, with clinical response and CSF pharmacodynamic profiling.
- The result: All patients had stable disease on days 14 and 30, 1 patient converted CSF cytology to negative through day 30, and QH104 persisted in CSF for at least 1 week with increased IFNγ and IFNγ-associated immune remodeling.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.